Rh disease is a condition where a pregnant person’s immune system attacks their baby’s red blood cells, causing the baby to become anemic before or after birth. It happens when the mother has Rh-negative blood and the baby has Rh-positive blood, creating a mismatch that triggers an immune response. Thanks to a preventive injection developed in the 1960s, Rh disease has gone from affecting roughly 13% to 16% of at-risk pregnancies to fewer than 0.2% today.
How Rh Disease Develops
Everyone’s red blood cells carry various proteins on their surface. One of these is called the Rh factor (also known as the D antigen). If your blood cells have it, you’re Rh-positive. If they don’t, you’re Rh-negative. About 15% of people of European descent are Rh-negative, with lower rates in most other populations.
The problem starts when an Rh-negative mother carries an Rh-positive baby. During pregnancy, small amounts of the baby’s blood can cross the placenta and enter the mother’s bloodstream. Her immune system recognizes the Rh protein as foreign and begins producing antibodies against it. This process is called sensitization. Those antibodies can then cross back through the placenta, latch onto the baby’s red blood cells, and destroy them.
A first pregnancy rarely causes serious harm, because the mother’s immune system is slow to mount a full response the first time it encounters Rh-positive cells. The real danger comes in subsequent pregnancies. Once sensitized, the immune system remembers the Rh protein and responds faster and more aggressively, producing antibodies in much higher quantities. Each successive Rh-positive pregnancy carries a greater risk of severe disease.
Why Some Couples Are at Risk
Rh disease can only occur when the mother is Rh-negative and the father is Rh-positive. If the father carries two copies of the gene for the Rh protein (homozygous), every baby will be Rh-positive and potentially at risk. If he carries only one copy (heterozygous), there’s a 50% chance each pregnancy will produce an Rh-negative baby, which carries no risk at all.
Sensitization doesn’t only happen during delivery. Miscarriage, ectopic pregnancy, amniocentesis, abdominal trauma, or any event that allows fetal blood to mix with maternal blood can trigger antibody production. This is why prevention needs to cover these situations too, not just full-term births.
What Happens to the Baby
When the mother’s antibodies destroy fetal red blood cells, the baby develops anemia. Mild cases may cause only slight jaundice after birth. Moderate cases lead to more significant anemia and jaundice, as the breakdown of red blood cells releases a waste product called bilirubin that the baby’s immature liver struggles to process.
In severe cases, the baby’s body tries to compensate by producing red blood cells in the liver and spleen, causing these organs to enlarge. If the anemia becomes extreme, the heart can begin to fail, and fluid accumulates throughout the baby’s body. This condition, called hydrops fetalis, is the most dangerous complication. Symptoms include total body swelling, severe anemia, breathing problems, heart failure, and purplish bruise-like spots on the skin. Without treatment, hydrops fetalis is often fatal.
After birth, the ongoing breakdown of red blood cells can push bilirubin to dangerous levels. When bilirubin rises above roughly 25 mg/dL in a full-term newborn, it can cross into the brain and cause permanent neurological damage, including hearing loss, movement disorders, and intellectual disability.
How It’s Detected
Screening begins early in pregnancy with a blood type test and an antibody screen (called an indirect Coombs test). If you’re Rh-negative, the test checks whether your blood already contains antibodies against Rh-positive cells. A negative result means you haven’t been sensitized, and preventive treatment can keep it that way.
If antibodies are detected, doctors monitor their concentration throughout the pregnancy. A rising antibody level signals that the immune response is intensifying and the baby may be developing anemia. The next step is confirming whether the baby is Rh-positive, which can now be done through a simple blood draw from the mother that analyzes fragments of fetal DNA circulating in her bloodstream.
For Rh-positive babies in sensitized pregnancies, the key monitoring tool is a specialized ultrasound that measures blood flow speed in an artery in the baby’s brain. When a baby becomes anemic, its blood gets thinner and flows faster to compensate. Measuring this velocity is 100% sensitive for detecting moderate to severe anemia, with a false positive rate of only 12%. This technique has largely replaced the need for riskier invasive tests like sampling blood directly from the umbilical cord. By tracking the rate of change over several consecutive weeks, doctors can identify which babies are heading toward severe anemia and will need intervention.
Treatment During Pregnancy and After Birth
When ultrasound monitoring shows the baby is becoming significantly anemic, an intrauterine blood transfusion can be performed. A needle is guided through the mother’s abdomen into the baby’s umbilical cord vein, and compatible red blood cells are transfused directly to the baby. Some babies need only one transfusion, while severe cases may require several at intervals of two to four weeks. This procedure is considered most successful specifically for fetal anemia caused by Rh disease, and it has dramatically improved survival rates for babies who would previously have died before birth.
After delivery, mildly affected newborns may need only phototherapy, where special lights help break down excess bilirubin in the skin. More severely affected babies may require an exchange transfusion, a procedure that gradually replaces the baby’s blood with donor blood to remove both the harmful antibodies and excess bilirubin. The decision to proceed depends on the baby’s bilirubin levels, gestational age, and whether they’re showing neurological signs like abnormal muscle tone, a high-pitched cry, or poor feeding.
Prevention With Anti-D Injections
The cornerstone of prevention is an injection of anti-D immunoglobulin, commonly known by the brand name RhoGAM. This product contains ready-made antibodies that find and destroy any Rh-positive fetal cells in the mother’s bloodstream before her own immune system has a chance to recognize them and form a lasting memory. It’s a form of immune interference: by clearing the foreign cells quickly, the injection prevents sensitization from ever starting.
The standard schedule includes one dose at 26 to 28 weeks of pregnancy and a second dose within 72 hours after delivery, once the baby is confirmed to be Rh-positive. Additional doses are given after any event that could cause fetal-maternal blood mixing, including miscarriage, amniocentesis, chorionic villus sampling, or abdominal trauma.
The impact of this prevention strategy has been dramatic. Before anti-D immunoglobulin became available in the late 1960s, sensitization occurred in 13% to 16% of at-risk pregnancies. After postpartum injections became routine, that dropped to 0.5% to 1.8%. Adding the routine injection at 28 weeks brought it down further to 0.14% to 0.2%. In the United States between 1996 and 2010, Rh disease affected between 44 and 99 per 100,000 live births, down from 106 per 100,000 in the 1980s.
Despite these advances, a small percentage of women (roughly 0.1% to 0.4%) still become sensitized during pregnancy even with proper treatment. This can happen when unusually large amounts of fetal blood cross the placenta, exceeding what the standard dose can neutralize. Once sensitization has occurred, anti-D injections no longer help, and the pregnancy must be managed through monitoring and, if needed, transfusion.
Why It Still Matters
Rh disease is sometimes described as a solved problem, but that’s only true when prevention is consistently applied. Sensitization still occurs when pregnancies aren’t identified as at-risk early enough, when injections are missed or given too late, or when earlier pregnancies (including miscarriages) weren’t properly managed. In parts of the world where anti-D immunoglobulin isn’t widely available, Rh disease remains a significant cause of fetal and newborn death. Even in countries with strong prevention programs, the condition hasn’t disappeared entirely, which is why universal blood type screening in early pregnancy remains essential.